Brief: Oncolytics Biotech Reports Interim Results From Phase 1/2 Goblet Study

Oncolytics Biotech

07/11/2022 14:33

Nov 7 (Reuters) - Oncolytics Biotech Inc  ONC.TO :
    * ONCOLYTICS BIOTECH® REPORTS INTERIM RESULTS FROM PHASE 1/2
GOBLET STUDY SHOWING A 70% OBJECTIVE RESPONSE RATE IN PANCREATIC
CANCER AT THE SITC ANNUAL MEETING
    * ONCOLYTICS BIOTECH INC - 70% OBJECTIVE RESPONSE RATE (ORR;
N=10)
IS NEARLY TRIPLE AVERAGE ORR OF ABOUT 25% REPORTED IN HISTORICAL
CONTROL TRIALS(1-4)
    * ONCOLYTICS - PELAREOREP SYNERGIZES WITH PD-(L)1 INHIBITORS
AND
STANDARD-OF-CARE CHEMOTHERAPY IN ADVANCED/METASTATIC PANCREATIC
DUCTAL ADENOCARCINOMA

Source text for Eikon:  ID:nCNWzxg4ca 
Further company coverage:  ONC.TO 
 ((reuters.briefs@thomsonreuters.com;))